Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních věcí,

kterým xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. x. x. a x. 46/2008 Sb. x. x.

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx dne 1. října 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx republiky podepsal xxxxxxx x xxxxxxx xxxx Xxxxxxx I Xxxxxx republikou.

Nové znění Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Českou xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx I x platnost xxx 5. xxxxxx 2019.

Dnem xxxxxx nového xxxxx Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx od 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx I x xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx text Xxxxxxx xxxx spravován XXXX x xxxx xxxxxxxxxx x angličtině a xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x francouzskou xxxxx xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Seznam bude xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX ROK 2018

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X METODY XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx S1, X2, S4.4, X4.5 x X6(x) a Xxxxxxxxxx metod M1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx zahrnuta x xxxxxxxxxxxxx sekcích Seznamu x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené pouze xxx veterinární xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* AAS, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:

Androstanolon (5α-dihydrotestosteron, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx a xxxxxxx, xxxxxx, ale xx x xxxxxxxx xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, např. xxxxxxx, LGD-4033, xxxxxxx x XXX140); tibolon; xxxxxxx a xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, ale ne x xxxxxxxx pouze xx ně:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx založené xx XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (xxxx. XXXX 530 x peginesatid).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xenon.

1.3 Xxxxxxxxxx GATA, např.

K-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného opravného xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx faktory, např. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx, u xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), jeho xxxxxxxxx x xxxxxxxxxx xxxxxxx, xxxxxx, ale xx x omezením xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a hGH 176-191; xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x xxxx analoga, xxxx. CJC-1295, xxxxxxxxxx x xxxxxxxxxxx; sekretagogy xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, např. xxxxxxxxxx, ipamorelin x xxxxxxxxxxx; uvolňující peptidy xxxxxxxxx xxxxxxx (XXXX), xxxx. alexamorelin, GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5, GHRP-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx a modulátory xxxxxxxxx xxxxxxx, včetně, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx růstový xxxxxx (XXX);

xxxxxxxx xxxxxxx růstový xxxxxx-1 (XXX-1) x xxxx analoga

mechanické xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x jeho xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx růstové xxxxxxx a modulátory xxxxxxxxx faktorů ovlivňující xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. BETA2- AGONISTÉ

Všichni xxxxxxxxxx x neselektivní xxxx-2 agonisté, včetně xxxxx xxxxxxxxx isomerů, xxxx xxxxxxxx.

Xxxxxxxx (ale xx x omezením xxxxx xx ně):

Fenoterol; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx po xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx dodaná dávka 54 mikrogramů xx 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x přítomnost formoterolu x xxxx x xxxxxxxxxxx xxxxx než 40 ng/ml nebude xxxxxxxxxx za zamýšlené xxxxxxxxxxxx použití, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx terapeutickou xxxxxx (v xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx dávka.

S4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx xxxx následující xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx xx x xxxxxxxx xxxxx na xx.

3. Ostatní antiestrogenní xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Agonisté Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) kyselina xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx x mimetika xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx chemickou strukturou x xxxxxxxxx biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); probenecid, xxx xx x xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; furosemid; xxxxxxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx a vaptany (xxxx. xxxxxxxxx), ale xx s omezením xxxxx xx ně.

S xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (např. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. krevní náhražky xxxxxxxx na xxxxxxxxxxx x mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx ne x omezením pouze xx ně. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx chemickými xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. proteázami) moči, xxx ne x xxxxxxxx pouze xx xx.

2. Nitrožilní xxxxxx x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX DOPING

Z důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx k xxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx S5 x X1 xx X3 xxxxxxxxx výše

jsou Při Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx zakázaná.

Stimulancia xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (d-);

mezokarb;

modafinil;

norfenfluramin;

p-metylamfetamin;

prenylamin;

prolintan.

Stimulancium, které xxxx výslovně xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx a xxxx xxxxxxx (xxxx. xxxxxxxx, methedron x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx zahrnuté xx Monitorovacího xxxxxxxx 2018 a xxxxxx xxxxxxxxxx xx Zakázané xxxxx.

** Xxxxx: xx xxxxxxxx pouze při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx a methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, např. xxxxx, xxxx xxxxxxxx nebo xxxx podání společně x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči je xxxxx než 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (XXX) x ostatní xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx glukokortikoidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx to xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx na xxxxxx x akrobatické xxxxxxxx-xxxxx x X-xxxxx, a xxxxxxxxx U-rampa x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx s xxxxxxxxx xxxx bez ploutví, xxxxxxxxx apnoe s xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx s xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Sb. x. x. nabyl xxxxxxxxx xxxx 26.7.2019.

Xxxxxx předpis x. 36/2019 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. s xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx změna xxxxx uvedeného právního xxxxxxxx.

1) Mezinárodní úmluva xxxxx xxxxxxx xx xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Xxxxxx, byla xxxxxxxxx v xxxxxxxxx xxxxx x x xxxxxxxxx do českého xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx vyhlášeno xxx č. 46/2008 Sb. m. s.